$-0.11
(Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.1
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
16,392,300
10 Years Aggregate
CFO
€-387.53 Mln
EBITDA
€-427.32 Mln
Net Profit
€-425.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
| -93.6 | -72.7 | -91.5 | -98.9 | -85.5 | -70.6 | -52.1 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
| -49.6 | -77.5 | -5.2 | 112.4 | -11.9 | 138.1 | -27.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
|
0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 |
| 4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 | |
| 2.3 | 309.5 | 0.0 | -39.1 | 281,529.0 | -41.7 | -- | 1.8 | |
| 37.0 | 2,546.3 | 0.0 | -171.6 | -- | -60 | -- | 7.3 | |
| 2.3 | 330.2 | 18.5 | -42.3 | -230.0 | -65.7 | -- | 3.5 |
Shareholding Pattern
View DetailsAbout Affimed N.V. - ADR
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for... CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Read more
-
Interim CEO, Chief Medical Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
-
Interim CEO, Chief Medical Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
-
Headquarters
Mannheim
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Affimed N.V. - ADR
What is the current share price of Affimed NV - ADR Today?
The share price of Affimed NV - ADR is $0.08 (NASDAQ) as of 18-Jun-2025 09:30 EDT. Affimed NV - ADR has given a return of -85.47% in the last 3 years.
What is the current PB & PE ratio of Affimed NV - ADR?
Since, TTM earnings of Affimed NV - ADR is negative, P/E ratio is not available.
The P/B ratio of Affimed NV - ADR is 0.06 times as on 18-Jun-2025, a 98 discount to its peers’ median range of 3.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Affimed NV - ADR?
The 52-week high and low of Affimed NV - ADR are Rs -- and Rs -- as of 28-Aug-2026.
What is the market cap of Affimed NV - ADR?
Affimed NV - ADR has a market capitalisation of $ 3 Mln as on 18-Jun-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Affimed NV - ADR?
Before investing in Affimed NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.